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ABSTRACT 
Primacy osteoarthritis (OA) of the knee is a common clinical problem. One non-
operative modality commonly used for symptomatic pain relief is an intra-articular 
corticosteroid injection. In rheumatoid arthritis patients, a period of rest post-
corticosteroid injection (i.e. decreased weight bearing on the extremity), has been shown 
to improve clinical response. This question has yet to be addressed for patients with 
primary OA of the knee. 
A twelve week randomized controlled trial was conducted in knee OA patients 
requiring an intra-articular corticosteroid injection into the knee. Forty-three patients 
were randomized to the rest group and forty-three to the no rest group. Patients in the rest 
group were instructed to keep weight bearing activities to a minimum for twenty-four 
hours after the injection. The no rest group had no physical restrictions placed on them. 
The primary outcome measure was the total WOMAC Index, which incorporates 
components of pain, stiffness and function. The WOMAC was measured at two, six, and 
twelve weeks post-injection. Repeated measures ANCOV A was used to analyze the 
primary outcome. 
This trial failed to demonstrate any short term clinical benefit of post-injection 
rest after an intra-articular corticosteroid injection in patients with primary osteoarthritis 
of the knee. 
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CHAPTER 1 INTRODUCTION 
6 
Primary osteoarthritis (OA) of the knee is a significant clinical problem and as 
population ages, the burden of this disease will increase. Primary osteoarthritis is a 
progressive "'wear and tear" arthritis that increases in prevalence after age 50. It is 
estimated that 25 - 30% of people aged 45 to 64 and more than 85% of people older than 
65 yearn of age have OA of the knee identifiable on radiographs (Cole et al). In 
comparison, secondary OA occurs after a known insult to the joint. Some common causes 
of secondary OA include intra-articular fracture, varus or valgus malalignment, and 
ligament or meniscal deficiency. 
Published in the proceedings of a conference sponsored by the American 
Academy of Orthopaedic Surgeons (AAOS) and National Institutes of Health was a 
definition ofOA: "Osteoarthritis is the result of both mechanical and biological events 
that destabilize the normal coupling of degradation and synthesis of articular cartilage 
and subchondral bone. Although it may be initiated by multiple factors including genetic, 
developmental, metabolic and traumatic, OA involves all the tissues of a diarthrodial 
joint. Ultimately, OA is manifested by morphologic, biochemical, molecular and 
biomechanical changes of both cells and matrix. This leads to softening, fibrillation, 
ulceration, and loss of articular cartHage, sclerosis, and eburnation of subchondral bone, 
and formation of osteophytes and subchondral cysts. When clinically evident, OA is 
characterized by joint pain, tenderness, limitation of movement, crepitus, occasional 
effusion, and variable degrees of local inflammation" (Keuttner et al.). 
It is the inflammatory component of this disease, and its treatment, which are of 
most interest here. OA is considered primarily a degenerative arthritis, particularly when 
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compared to primary inflammatory arthropathies such as rheumatoid arthritis. The 
inflammatory component of OA is thought to be secondary to the articular cartilage 
degeneration, however histiologicaUy the changes in the synovium are similar. 
These histologic changes vary, depending on the stage of disease. The acutely 
inflamed joint early in the disease process has synovium with marked hyperplasia and a 
dense cellular infiltrate composed mainly of lymphocytes and monocytes. Toward the 
later stages of the disease, in "burned out" joints, the synovial membrane is thickened by 
fibrotic tissue, with little cellular infiltrate. The histology of OA is similar to 
inflammatory arthropathies, with the degree of inflammatory changes less in the 
synovium affected with OA (Harooui et al. ). 
This inflamed synovium can produce substances that directly degrade articular 
cartilage. This synovium expresses high levels of inflammatory cytokines such as TNF -a 
and IL-l. These two factors stimulate MMP's, COX-2, and nitric oxide synthetase that 
directly degrade articular cartilage. Nitric oxide has recently been implicated in the 
pathogenesis of OA. It produces free radicals that result in an increase in chrondrocyte 
apoptosis and this decline in chrondrocyte numbers impairs the ability of the articular 
cartilage to maintain homeostasis and promote repair. (lJlrich-Vinther et al.) 
Patients with osteoarthritis of the knee present primarily for treatment of pain. 
Two components of the disease probably combine to cause this pain. Cartilage 
destruction causes mechanical or skeletal pain. The inflammatory component results in 
pain through a separate mechanism. 
Bone is rich in afferent nocioreceptors. Recent opinion was that the vast majority, 
if not all, of these fibers exist in the periosteum ofbone (Mundy). This rich bed of nerve 
fibers would explain the severe pain is present with a fracture in the 
periosteum has been disrupted. As the intracapsular or articular component of the bone is 
devoid of any periosteum, the conclusion that joint damage and exposed ebemated bone 
in isolation may not be painful could be drawn. Recent work in a rat model (Mach et al.), 
has shown that bone and bone marrow have sensory fibers. With an antibody labeling 
technique, the presence of myelinated and unmyelinated sensory fibers was 
demonstrated. These fibers could have a coordinated role in the generation of bone pain 
in patients with OA. As cartilage is completely lost and subchondral bone is exposed, the 
presence of these nerve fibers in bone may explain one pathway for pain in these knees. 
Pain also results from the significant inflammatory reaction that can be present in 
osteoarthritic knees. As the course of the articular cartHage component of the disease is 
one of slow, continuous deterioration, it is the pain due to inflammation that causes the 
waxing and waning pattern often seen. Periods of severe discomfort with joint swelling, 
warmth and erythema may be interrupted by periods when the joint is relatively pain free. 
This inflammation stimulates the abundant pain fibers within the synovium and joint 
capsule. 
The goal of treatment for OA is to lessen the burden of this pain. Pain in a joint 
will negatively affect its role thus affecting overall patient functioning and quality of life. 
Secondary goals of treatment include improving range of motion, correcting deformity, 
and preventing/slowing disease progression. Although total joint arthroplasty has been 
successful, it is only needed in a small proportion of patients with knee arthritis. Most 
patients avoid or delay surgical treatment with the many non-operative modalities that are 
available. Despite the varying success in relieving pain, no medical therapies to date have 
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been shown to prevent or slow joint degeneration, i.e. change the natural history of the 
disease. (Ulrich-Vinther et at) 
Treatment regimes for symptomatic osteoarthritis address different components of 
the disease. Joint deformity, either congenital or secondary to cartilage destruction or 
traumatic joint injury, can be treated with bracing or corrective surgery (osteotomies). 
Replenishing lost or degenerated articular cartilage has proven to be a formidable task. 
Replacing lost articular cartilage with osteochondral graphs, either allographs or 
autographs, has had variable success. Replacing lost cartilage and chondrocytes with 
tissue grown in tissue cultures has some promise but remains far from clinical use. The 
inflammatory component of the disease is often treated with systemic modalities 
(NSAID's) or local modalities (intra-articular corticosteriods). 
In 2000, the American College of Rheumatology published recommendations for 
the non-surgical management ofOA. (American College ofRheumatology 
Subcommittee). Nonpharmacologic therapy include education, weight loss, exercise 
programs and physiotherapy, assistive devices (cane), bracing and shoeware 
modifications. Pharmacologic therapy often starts with a mild analgesic. Acetaminophen, 
up to 4 grams per day, is generally well tolerated and is effective in mild to moderate 
disease (Bradley et aL ). More severe disease or failure of acetaminophen therapy requires 
the use of non-steroidal anti-inflammatory drugs (NSAID's). Multiple authors have 
demonstrated the effectiveness of these medications over both acetaminophen and 
placebo and the side effects are well known. (Wolfe et al., Pincus et al., Altman et al.) 
Gastrointestinal side effects are the most problematic for the traditional NSAID's but 
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newer selective COX-2 inhibitors have a lower incidence of these problems. (American 
College of Rheumatology Subcommittee) 
If these initial treatment modalities fail to adequately control a patient's 
symptoms, intra-articular therapies are often the next step. Recently, an intra-articular 
injection of a hyaluronic acid analog has been used. Hyaluronic add is a component of 
synovial fluid and has been shown to be present in a lower concentration in knees with 
osteoarthritis. An analog of hyaluronic acid has been synthesized and has been shown to 
temporarily decrease the symptoms of OA of the knee when injected into the joint 
(Altman et al., Dougagos et al, Scale et al., Wobig et al.). Most regimes involve three 
injections separated a week apart and can provide six months to a year of improvement in 
pain level and functioning (Watterson et al.). 
Viscosupplementation is not without concerns. Drug regulating bodies have 
classified these injections as medical devices. Thus, they have not had to meet the 
stringent safety and efficacy requirements of a drug. Although some trials have shown a 
clinical benefit, others have not demonstrated any improvement over placebo (Dahlberg 
et al., Henderson et al., Lomander et al.). In a recent prospective, randomized trial 
(Leopold et al.), viscosupplementation has not been proven to provide any better clinical 
result than intra-articular oorticosteriods. 
Adverse reactions of viscosupplementation have been reported. A local 
inflammatory reaction has been seen in up to eight percent of patients. This reaction is 
often severe, resembling a septic joint. Reactions are usually transient and no systemic 
effects have been reported. (Watterson et al., Lussier et al., Pyron et aL) Cost is often a 
prohibitive factor. A course of injections can cost hundreds of dollars. 
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Total joint mtbroplasty had revolutionized the treatment of end stage OA of 
the hip and knee and its success is well documented (Hanssen et al.). In. patients who 
have failed non-operative treatment, TJA frequently results in a dramatic decrease m joint 
pain and an improvement overall functioning. This procedure, despite its overall 
success, is not without it concerns. Deep infection and component dislocation can be 
serious problems and the devices do not have an infinite lifespan. Total joint arthroplasty 
is a less attractive option in patients younger than sixty years of age. (Ranawat et al.) 
These patients are more active and "wear out" their artificial joint at a faster rate than an 
elderly, more sedentary individual. Revision or redo surgery for a failed total joint 
arthroplasty produces inferior results compared to the primary procedure. (Ewald et al.) 
Younger arthroplasty patients will frequently require multiple complicated surgeries 
years after the index procedure. (Hanssen et aL) It is these concerns that leaves TJA for 
end stage disease in patients that have exhausted all non-operative modalities. 
1.2.1 Prevalence and mechamsm of adion 
A mainstay of treatment for OA of the knee has been intra-articular corticosteroid 
injections. First described in 1951, these injections have been used very commonly with 
some benefit and minimal risks. One survey of 223 orthopaedic surgeons revealed that 
each used intra-articular steroids on average 150 times per year (Fadale et al). 
The mechanism of action of corticosteriods has been well documented. 
Corticosteriods are naturally occurring substances. They are sy"Dthesized from a 
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cholesterol foundation the adrenal cortex. Corticosteriods produce an effect, to varying 
degrees, on most metabolic processes within the body. 
These substances pass freely through the cell membrane and bind to receptors 
within the cytoplasm. This steroid- receptor complex can then enter the cell nucleus and 
alter RNA synthesis. The end result is an alteration of enzyme production and thus can 
have effects on all systems ofthe body. 
Of most interest here is the effect of corticosteriods on inflammation. 
Inflammation is the first of four stages in the healing process. Inflammation clinically is 
characterized by pain, stiffness, redness, swelling and heat. During this inflammatory 
phase, there is increased cellular membrane permeability and edema results. Leukocytes 
and macrophages are drawn to the area by chemical mediators. Macrophages remove 
dead cellular material and the leukocytes release hydrolytic enzymes producing 
arachidonic acid by hydrolysis of cell membrane phospholipids. It is the production of 
arachidonic acid that is altered by the corticosteriods. 
Corticosteriods inhibits phospholipase A2. Phospholipase A2 catalyzes the 
breakdown of membrane phospholipids to arachidonic acid thus disrupting the 
inflammatory cascade. The latter three steps in the healing process, repair, remodelling, 
and maturation phases are less affected (Fadale et al.). 
1.2.1 Review of emeag of eom~®steroid bee mi"tions 
The pain relieving benefits of intra-articular injections have been previously 
studied. Several randomized trials have been conducted and have showed either a mild, 
temporary benefit -2 weeks) (Dieppe et al., Friedman et al.) or no benefit over placebo 
13 
(Cederlof et al). Recently a meta~analysis of intra-articular steroids for of the knee 
has been completed (T owheed et al. ). It demonstrated a role for intra-articular steroids in 
the short-term management ofOA ofthe knee. No evidence has shown a lasting benefit 
(> 1 month) from these injections. 
Many different corticosteroid preparations are available for intra-articular 
injection but there are no firm guidelines on deciding which drug to use. Water solubility 
seems to affect duration of action with the more water soluble compounds having a 
shorter duration of action. Water insoluble preparations are often used for chronic 
inflammatory conditions and more water-soluble used for more acute conditions. No 
clinical literature is available to support these trends with drug choice based solely on 
these theoretical principles (Fadale et al.). 
Dosage of steroid used also lacks firm recommendations. In current clinical 
practice, the amount of steroid used is proportional to the size of the joint to be injected. 
Presently, the clinical practice at our institution is to use 40 mg of methylprednisolone 
acetate (Depo-Medrol) in a knee joint. Methylprednisolone acetate is cheap, readily 
available and is only slightly water-soluble (Fadale et al.). 
There is debate about the safety of these drugs used intra-articularly. Although 
there is contradictory evidence (Pelletier et at), it is felt by some investigators, based 
mainly on animal model work, that intra-articular steroid is deleterious to articular 
cartilage. In an animal model it has been show--n that the steroid causes a decrease in 
cartilage- matrix production (Behrens et al., Mankin et al.). The drug inhibits 
chrondrocyte proliferation and decreases matrix synthesis and it blunts the response to 
important growth factors such as TGF-p. There is no firm evidence, however, to show in 
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humans that intra-articular steroids, while relieving pain, speeds articular surface 
deterioration. This may be impossible to determine, as it will be difficult to show the 
steroid has a clinically relevant negative effect on articular cartilage structure when the 
natural course ofthe OA is progressive cartilage destruction. 
The best evidence that addresses the clinical safety of intra-articular corticosteroid 
injections is recent work performed in Montreal (Raynauld et al.). This was a 
randomized, double blind, placebo controlled trial of intra-articular corticosteriods for 
OA of the knee. The investigators compared saline injections to corticosteroid injections 
every three months (regardless of pain relief) for two years. Radiographic loss of joint 
space was the primary outcome measure. The investigators felt that increased articular 
cartilage destruction secondary to these frequently administered corticosteroid injections 
would cause a decrease in the radiographic joint space. The trial failed to show any 
significant difference in the rate of joint space loss between the experimental and control 
groups. Thirty-four patients were in the experimental group and no adverse effects, 
either clinical or laboratory, were reported. 
These joint injections are not truly local therapy. There is some systemic 
absorption of the intra-articular corticosteroid injection. The water solubility of the 
preparation is proportional to the amount of systemic absorption and suppression of the 
hypothalamus - pituitary - adrenal axis for two to seven days has been shown with high 
doses. Therefore only one large joint should be treated per visit and injections should be 
spread out over as long a time period as possible (Gray et al.). 
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This systemic absorption of the steroid may be responsible for reports of pam 
relief m joints other than the one injected. This is lrnoWIJ. as the "spill over effects" and is 
reported mainly patients with primary in.flammatmy arthropathies. 
Despite the theoretical concerns, side effects are very un.usual and allergic 
reactions have been rare. This form of therapy has been used for at least thirty years 
has a proven to be effective and safe (Kumar et at). Unlike hyaluronic acid injections, 
cost is not a prohibitive factor. 
Indications, contraindications, and method of injection cause little debate. 
Indications would include an osteoarthritic lrnee, diagnosed on clinical history, physical 
exam and plain radiographs, that has failed management with less invasive therapy such 
as NSAID's, physiotherapy, activity modification and walking aids. Contramdications 
would include knoWIJ. hypersensitivity to the corticosteroid or an active infection at the 
injection site. 
The post injection management for these patients varies between physicians. 
Some suggest the patient remain non-weight bearing for a period of time (24-48 hours) 
post-injection and others allow the patient to be as active as the pam allows \vithout any 
specific restrictions. The physicians who restrict their patients drum an improved 
symptomatic response to the injection and a longer duration of benefit. Others argue that 
restricting the patient's activity 
outcome. 
not provide any appreciable improvement in 
1.3 Rest ~md it~ Effm om Arthritis 
Rest has been a form of treatment for arthritis for centuries. During the 1970's 
and early 1980's, patients with acute exacerbations of arthritis would routinely be 
admitted to hospital for strict bed rest for weeks or months. Joints would be immobilized 
with splints or casts. This regime was most frequently used for patients with 
inflammatory arthropathies. There are some theoretical benefits of rest in patients with 
inflammatory arthropathy. This has been mainly broken down into inflammatory and 
mechanical factors. 
The intensity of the inflammatory response in an affected joint is worsened with 
activity. In both a rat and a rabbit model (Smith et al.), activity increased synovitis and 
inflammation compared to immobile joints. Increased motion also seems to increase joint 
effusions. Intra articular pressure is increased as well as synovial collagenase activity. 
This is thought to accentuate articular cartilage destruction, bony erosions and 
subchondral cyst formation. 
Mechanical factors influenced by rest also have a role. Shear, torsion and tension 
are harmful to articular cartilage but are lower in magnitude than compressive force 
caused by weight bearing. Unloading the joint with bed rest reduces these forces. 
Along with the theoretical benefits, proponents of rest treatment cited evidence 
demonstrating the safety of joint immobilization for up to four weeks and that patient's 
acute exacerbation settled more quickly with rest (Partridge et al.). It was also felt, 
without good evidence, that rest may decrease the constitutional manifestations of the 
disease (Partridge et al). 
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Rest in not benign, cheap or easy to enforce. Prolonged rest results in muscle 
atrophy, osteopenia, and joint stiffness. There is an increased risk ofthromboembolic 
disease, pneumonia, and skin problems. Not to be ignored are the psychological effects of 
this treatment. Direct financial cost is incurred with forced rest Hospital beds and 
nursing care are expensive and in short supply. Missed work by patients resW.ts in 
significant indirect costs and compliance is difficult to enforce (Smith et al. ). 
Several investigators have attempted to answer the question whether or not forced 
rest has any clinical benefit, both short and longer term, in patients with inflammatory 
arthropathies. Prior to the 1970's, no good evidence existed for its use. Rest was 
commonly included in treatment regimes but was never studied as an isolated variable. 
MiHs et al. performed a single blind randomized controlled trial that used rest as the only 
independent variable. Included were hospitalized patients with RA who continued with 
their usual medical management throughout the trial. Outcome measures included joint 
range of motion, number of swollen and tender joints, grip strength, walking time, ring 
size and sedimentation rate. The investigators coW.d not demonstrate a statistically 
significant difference between the rest and activity groups in any of the outcome 
1.4 Review of tbe Literature 
Very little research has been completed on the combination of a rest and intra-
articW.ar steroids use in arthritis. This paucity of evidence has resW.ted in the wide variety 
of post injection regimes in clinical practice. One paper by Chakravarty et at, tackled the 
question of efficacy of rest after an intra-articular corticosteroid injection into the knee. 
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TI'ris was performed patients vvith an inflaJTmatm'Y arthropathy. It was a JJ:'fu"ldomized 
controlled trial of ninety-four patients who had a steroid injection into the knee for pain 
non-responsive to other non-invasive modalities. Patients who were :randomized to the 
rest group were admitted to hospital for twenty-four hours of strict bed rest while the 
control group were sent home with no particular restrictions on their activity. The groups 
were randomized using random number tables and appeared similar in some common 
variables (age, sex, duration of disease, and type of inflammatory arthropathy). The entire 
group would reasonably represent this patient population and no patients were lost to 
follow-up. 
No validated scoring system was utilized as an outcome measure. Pain and 
stiffness was assessed using a ten centimetre visual analog scale. Knee circumference and 
fifty foot walking time was also measured. Laboratory assessments included a complete 
blood count, erythrocyte sedimentation :rate and C-:reactive protein. These outcome 
measures were collected at the time of injection and three, six, twelve, and twenty-four 
weeks post injection. 
Using a statistical measurement tool by Matthews et al., the investigators found 
that the overall improvement of each outcome measure during the time frame of the study 
was better in the rest group compared to the no rest group. These findings were 
statistically significant (p<0.05). Erythrocyte sedimentation rate and C-reactive protein 
also demonstrated an overall improvement in the study group. Pattern of improvement 
was not explicitly explained. The paper includes graphs of scores for each outcome 
measure for ten "representative" patients. It appears from the graphs that improvement 
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early (3 and 6 weeks) was similar for both groups, 
the rest group fared better. 
at later times (12 weeks) 
Seventeen percent of the patients did not complete the trial. These patients 
required a change in treatment for their knee synovitis due to a recurrence of their pain 
during the treatment period. This change treatment was defined as a change or addition 
to their medical treatment, the necessity of a repeat steroid injection into the study knee, 
or an injection into another joint A greater number of patients from the non-rest group 
had to withdraw, but this finding was not quite statistically significant (0.05 < P < 0.1 ). 
There are some criticisms of this paper. Firstly, the assessors were not blinded 
this study. Although blinding would have been ideal, most of the outcome measurements 
were completed by the patients (i.e. the visual analog scales and fifty foot walking times) 
or were objective lab values. This is probably not a fatal flaw in the study design. 
This paper used non-standardized outcome measures which introduces two 
concerns. It makes comparison of the results of this paper to others difficult such as in a 
meta-analysis. Also the reader is not certain if the outcome measures used are sensitive 
enough to pick up a clinically relevant difference. 
Another problem with extrapolating the results of the previous study in RA to our 
study in primary OA is that these are two different disease processes. The outcome 
measures selected in the above study are not relevant for primary knee OA . 
The most significant limitation of this paper was the practicality of the 
intervention that is being proposed. The effect size of the improvement is likely to be 
small and thus the impact regarding cost effectiveness miDimal. In our present Canadian 
health care system, forced and monitored rest for twenty four hours in a hospital setting 
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for an arthritis patients after a :corticosteroid injection into ilie knee wollid likely not be 
feasible. 
The concerns mised with the use non-standardized outcome measurement tools 
have spawned the development of standardized, validated outcome measures that are 
often disease specific. The measurement tool selected for this trial was the WOMAC, the 
Western Ontario, McMaster Osteoarthritis Index (Appendix 2). Its pu.rpose is to measure 
clinically significant, patient relevant symptoms of pain, stif:fu.ess, and physical function 
in patients with osteoarthritis of the knee following intervention. (Bellamy et al.). Using a 
twenty four item questionnaire, three dimensions are measured, with subscales of pain, 
stiffness and function. All questions relate to the patient's experiences over the past forty-
eight hours. 
There are two versions available, a five point Likert scale and a 1 OOmm horizontal 
visual analog scale. The Likert scale chosen here uses descriptive adjectives: none, mild, 
moderate, severe and extreme, which are translated into a numeric, ordinal scale (0-4). 
Total WOMAC score is a continuous variable representing an average of each subscale. 
Lower scores indicate a lower level of dysfunction. (Bellamy et aL) 
Reliability, validity, and sensitivity/responsiveness to change has been extensively 
studied and results are generally positive. The pain and function subscales exhibit 
comparable or greater responsiveness than similar dimensions on the SF-36. (Rogers et 
aL) Not unlike other disease specific scales, the WOMAC is not immune to influence by 
ot.~er patient factors. Fatigue, depression, symptom counts, and low back pain, though not 
directly measured by the scale, seem to influence soores. (Wolfe) This measurement tool 
has been extensively used in the orthopedic and rheumatology literature. 
A literature search revealed no randomized trials that attempted to answer the rest 
versus no rest question in patients with primary knee osteoarthritis. the 
demonstrated clinical success of corticosteroid injections in OA patients, the recognition 
of the inflammatory component of osteoarthritis and the evidence to suggest that post 
injection rest is helpful in inflammatory arthropathies, many clinicians today recommend 
a period of rest in OA patients after injection. However, there is no direct evidence to 
support this practice. RA and OA are different disease processes and extrapolating the 
results of Chakravarty et al. to OA patients may not be valid. Thus a trial was designed to 
answer our research question. 
1.5 Research Question 
"Does a rest period of twenty four hours after an intra-articular steroid injection improve 
the magnitude and duration of pain relief in patients with osteoarthritis of the knee." 
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The research question was addressed with a randomized controlled mat Patients 
with primary osteoarthritis of the knee who had failed traditional non-invasive treatment 
were recruited for me smdy. They were randomized to either a period of rest (study 
group) or to non-restricted activity (control group) after an intra-articular steroid 
injection. 
1.1 Subied Seledio~ 
Patients were recruited from outpatient Orthopaedic clinics. Patients were 
approached and asked to participate in om smdy if they met inclusion and exclusion 
criteria that had been established. 
2.1.llnelusion Criteria 
1. Primary osteoarthritis of the knee. Diagnosis based on clinical and radiographic 
findings and AAOS definition of OA. The diagnosis was made by the attending 
physician. 
2. Non-invasive modalities of treatment, i.e. activity modification, NSAID's, have 
failed to satisfactorily control symptoms of pain and swelling. The attending 
physician has decided on treatment with an intra-articular corticosteroid injection. 
3. Patient available for follow up during me study period. 
4. Patient's informed consent expressed via signature on consent form. 
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1. Contraindication to intra-articular corticosteroid injection. (i.e. undesirable 
reaction to previous injection or active infection at the injection site.) 
2. Inability to comply with a period of rest (Reasons may include occupation or 
personal commitments that would make this rest period unacceptable.) 
3. Inability or unwillingness to provide informed consent. 
2.1 Rapdommation and Sample Size Calculation 
Patients were randomized to the study or control group by the use of a coin toss as 
each subject is recruited. Heads - study group, tails - control group. 
Our primary outcome measure was the total WOMAC score. Previous studies 
have reported a mean score of 10.3 with a standard deviation of 4.4, among patients with 
primary OA. We set a clinical difference of20% as being clinically relevant. With a= 
0.05 and 13 = 0.20, a sample size of 39 patients per group was calculated for each group. 
Assuming a dropout rate of 10%,43 patients per group (86 total participants) were 
required to answer our research question. 
2.3 Inte.nrention 
When the inclusion criteria were met and informed consent was obtained 
(Appendix 1), the patient was either assigned to the control or experimental group. 
Regardless of assignment, the attending physician carried out a corticosteroid injection 
into the affected knee using 40 mg of methylprednisolone acetate (Depo-Medrol). The 
treating physician was not aware which of the two groups a patient was allocated. 
25 
With ru1 assiglli1r!lent to the control group, the patient was discharged from the 
clii!.ic with no restrictions on their activity. They were informed to perform any desired 
activity vvithln the limits of their discowJort. 
With assignment to the study group, patients were asked to rest for twenty-four 
hours after injection. Rest was defined as only the necessary walking required for the trip 
home (i.e. from the clinic to the car and from car to house) and the walking at home 
necessary for meals and personal hygiene. 
2.4 Outeom® Me~surement 
The primary outcome measure was the total soore of the WOMAC which 
includes the pain, stiffness and function subscales. A standardized questionnaire was 
administered to the patient, including demographic information, concomitant therapy, and 
disease related factors (appendix 2). Specifically, we recorded the age at the time ofthe 
study, sex, and analgesic use (i.e. NSAID's, acetaminophen, opiates, or natural remedies) 
in the 48 hours preceding injection as well as the number of previous steroid injections 
into the same knee. The parameters noted above were ascertained by a single study nurse 
who was well acquainted vvith the protocol. The patients then were provided the 
WOMAC questionnaire which was completed during the initial visit Subsequent 
WOMAC measurements were retrieved by telephone at 2 weeks, 6 weeks and 12 weeks 
post injection. Adverse reactions, if any, were documented systematicaHy in the study 
sheet The patients were not prompted regarding any particular side effect. In an attempt 
to standardize the data collection procedure, a single study nurse was employed and a 
script was followed during coHection of data over the telephone (Appendix 3). 
26 
Compliance with intervention was assessed by asking volu.11teers in ilie 
rest group, at the two week dam collection point, if they indeed complied with the request 
to rest. As a broad measure for global satisfaction for both groups the volunteers at 2 
weeks were asked if they had their time back, would they stiH have had the intra-articular 
injection performed. 
Study design is summarized in Figure 1 
Patient Identified with Dx of Knee OA 
I Patient to Receive 'lA Steriod ln·ecfon I I j ! I 
NO YES 
Not Study Candidate II Patient Meets Inclusion Criteria & I 
. Consent Obtained to Participate 
NO YES 
Not Study Candidate WOMAC Completed 
Other info collected 
N=86 
I 
lA Injection Performed i 
N=86 I 
I I Patient Randomized I 
N=86 
Res! No Res! 
Patient Instructed 
I 
No Activity I 
to Rest Restriction I N=43 N=43 
I I 
I 2WeekWOMAC 2WeekWOMAC N=43 N=43 I Compliance with rest ? Would you have it agai n? 
Would you have it again? 
I 
I 6 Week WOMAC I 
N=41 
Figure 1 Study Design 
I 
! 6 Week WOMAC I 
N=41 
1 12 Week WOMAC 
N=38 
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1.5 Analysis 
The two groups were compared to look at the similarity of the baseline 
parameters. Chi-squared analysis was performed for the following categorical variables 
as all the cells had at least 5 subjects: sex, side, previous corticosteroid injections, and use 
of any medication in the last forty-eight hours. For the continuous variables (age of 
subjects at time of study), student t-test was used. 
Mean WOMAC scores were calculated for each subject at each of the four data 
collection points (immediately preceding injection, and 2, 6, and 12 weeks post 
injection). Statistical testing involved Repeated Measures Analysis of Co-Variance 
(ANCOV A) for both total WOMAC score and the pain subscale. The pain subscale was 
singled out as some investigators feel this is the most relevant parameter to assess 
efficacy of medical interventions as the treatment goals are primarily focused on limiting 
pain. (Robertsson et al.) 
A multiple linear regression analysis was conducted to assess if any patient 
parameters helped predict response. The dependent variable was the change in the 
WOMAC score. The independent variables included, age, sex, number of previous 
cortisone injections, and analgesia use. 
All statistical analysis was carried out using SPSS Version 11.0.1. (SPSS Inc. 
Chicago, IL.) 
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1.6 Ethical bsues and Consent 
Study design and implementation met all the guidelines of the Tri-Council's 
policy statement of August 1998. Approval by the Human Investigations Committee at 
Memorial University of Nevvfoundland and Health Care Corporation of St. John's was 
granted (Appendix 4 & 5). Signed informed consent was obtained from all study subjects 
and subjects were reassured that they were free to leave the study protocol at any time. If 
a subject chose not to become involved in the study after the injection was given, post 
injection activity level was at the discretion of the attending medical staff. 
Patient confidentiality was strictly protected. All patient records were treated as 
hospital charts and were stored safely under lock and key. 
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Eighty-six patients were recruited to the study from outpatient orthopedic clinic 
between October 2001 and May 2002. Seventy-five (88.4%) patients completed the full 
twelve-week protocoL Eighty-two (95.3%) completed six weeks and all patients 
completed the two-week questionnaire (Figure 2). The reasons for withdrawal included: 
seven patients had repeat injections due to increase in symptoms, two patients had total 
knee replacements, one patient became incapacitated for medical reasons, and one could 
not be contacted. 
Figu:re 2 
Patients completing FoUow-up 
2 12 
Time (Weeks) 
Forty-three patients were allocated to each group. Using a Chi-Square analysis, 
the groups were compared for homogeneity. (Table 1) 
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Rest No Rest 
# of Patients 43 43 
63.5 (14.2) 63.8 (13.0) Mean Age (S.D.) 
Side (R or L) 
Meds Taken last 48h 
R21 L22 R22 L21 
28 (65.1%) 30 (69.8%) 
Previous Injection 25 (58.1%) 22 (51.2%) 
Total WOMAC scores were then analyzed (Table 2 and Figure 3). 
Tablel Injection 2 weeks I 6weeks 
Rest (S.D.) 2.32 (0.829) 1.54 (0.961) 1.65 (0.775) 
No Rest (S.D.) 
1 
2.26 (0. 780) 1.48 (0.879) I 1.49 (0.957) l 
Mean WOMAC scores (Total) 
P value 
0.913 
0.700 
0.451 
12 weeks 
2.12 (0.942) 
1.79 (L064) 
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4 
m~inl WOMAC ~c~o~rs 
Figure 3 
! 3 +-----T---------------------------------~--
0 
~ p,n I 
u 2 +---~r-~~----~--------~-------=-~+---- ) -+-No Rest I ~~ 
~ I 
1 I 
0 +,----------~--------~--------~--------~ 
± 
Injection week2 week6 week 12 
Efficacy of the injections was considered. The mean WOMAC score improved in 
both groups that maximized at week 2 but continued even until week 12. Paired T-tests 
were performed comparing week 2, 6, and 12 to the baseline score at injection for each 
group. These tests do not take into account the time line; it was performed to demonstrate 
that the injections do provide a clinical benefit (reduction in the WOMAC score) at most 
of our data collection points in both groups. At 12 weeks the no rest group score was 
slightly above statistical significance when compared to score at injection. (Table 3) 
I 
I 
P value on Paired I P value on Paired Tabl€! 3 Samples T -test (Rest I Samples T -test (No 
Group) Rest Group) 
I 
Injection- 2 weeks P<0.001 P<O.OOl 
Injection- 6 weeks P<O.OOl P<0.001 
I 
Injection- 12 weeks 
I 
P=0.020 P=0.074 
I 
i 
Baseline Comparison (Total W0t4AC Score) 
33 
I 
I 
I 
I 
J 
To ru1.swer our research question, a comparison of the total WOIV1AC score of tc'J.r.e 
study and control group was then completed with a Repeated Measures analysis of co-
variance (A.l\ICOV A) which produced a p value of 0506. 
The primary purpose of intra-articular steroid is pain relief and relief of pain 
correlates well with patient satisfaction (Robertsson et al). We reanalyzed the groups 
using only the pain subscale of the WOMAC with an ANCOVA test and again failed to 
demonstrate a difference between the study and control groups (p=0.710). The paired 
samples t -test was repeated for the pain subscale and it demonstrated a reduction of pain 
in both groups at each data collection point (Tables 4, 5 and Figure 4) 
Table4 Injection 2 weeks 6 weeks 12 weeks I 
l 
Rest (S.D.) i 2.15 (0.932) 1.35 (1.01) 1.34 (0.858) 1.75 (1.11) I I 
No Rest (S.D.) 2.28 (0.931) 1.23 (0.947) 1.44 (1.09) 1.88 (1.23) 
Mean WOMAC scores (Paln Sunscale} 
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Mean ............. ., .... "'"" Score (Pain '"'uiu~!l;i;c~mu 
Figure 4 
4 
3 +----3!':--------
0 +----------r--------~----------~------~ 
Injection week2 weekS week 12 
Table 5 P value on Paired samples T -test 
Injection - 2 weeks p <0.001 
Injection - 6 weeks p < 0.001 
Injection- 12 weeks p = 0.008 
Basel1ne Coropar1son (Paln Subscale WOY~C Score) 
The ANCOV A accounts for the fact that the data was repeatedly collected at various 
points in time on the sample subjects. T -tests were performed at each data collection 
point to simply compare the study and control groups at each point in time for both the 
total WOMAC score and the pain subscale. No statistically significant results were 
demonstrated. These findings are summarized Table 6. 
35 
I 
Table6 Week2 Week6 ~~ Week 12 ~-----------+------------+-------------·~! ----------~ Rest vs No Rest 1 
(Total WOMAC) 
Rest vs No Rest 
(Pain Subscale) 
I 
I 
I 
I 
P=0.764 
p =0.600 l 
I 
p = 0.598 p = 0.542 
p = 0.665 
I 
p = 0.643 
Comparison of Study and Control Group (Total Score and Pain Subscale) 
The re-injected patients were analyzed. Of the seven patients, t.hree were from the 
No Rest group and four from the Rest group. This small group was then compared to the 
rest of the entire sample using an independent samples t-test and no significant difference 
was found in WOMAC scores at baseline (p=.385), week 2 (p=0.518), or week 6 
(p=0.594). 
I Reinjected Group Non-Reinjected Table 1 (Mean WOMAC Group (Mean PValue I 
I 
Score) WOMAC Score) 
Baseline 2.52 2.24 P=0.385 
2 weeks 1.22 1.45 I P=0.518 
6 weeks 1.69 1.49 ! P=0.594 
I 
Comparison of RelnJected and Non-relnJected Groups 
Multiple regression analysis was then performed to determine if any variables 
were predictive of WOMAC Scores. The variables thought to be clinically relevant and 
possibly significant were, previous cortisone injection, age, and concomitant use of 
NSAID's. These three variables were tested at 2, 6 and 12 weeks using a multiple 
regression analysis m1d no statistically significant correlations was noted at 5% 
significance level. 
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' 
I 
I 
All patients in the study group, when asked at the 2 week point, smted they 
complied with the period of :rest 
Eight-five of eight-six (98.8%) of patients at the 2 week point stated that if they 
hoo their time back, they stm would have had the injection. Thus the injection was 
helpful for both the groups studied. 
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DiKussiop 
Corticosteroid. injections into the knee in patients with OA is a time honoured 
treatment that goes on countless times daily in orthopedic and rheumatology clinics 
throughout the world. There is research to suggest it is beneficial in the short term. but its 
role in definitive treatment for OA is smalL It gets patients through flare-ups oftheir OA 
and may be used repeatedly in older, unweH patients that are not candidates for 
arthroplasty. 
Unlike inflammatory arthropathies such as rheumatoid arthritis, osteoarthritis is 
primarily a mechanical, degenerative disease, with a secondary inflammatory component 
It is this known inflammatory component that explains the efficacy, at least in the short 
term, of intra-articular corticosteriods in patients with OA. Combining this therapy, with 
another known treatment for arthritis, namely rest, has been shown to be helpful in 
patients with inflammatory arthropathy. Despite the paucity of evidence to suggest it, the 
effectiveness of this combination has been extrapolated to include patients with a 
primarily degenerative arthritis. There is no evidence to scientifically allow this 
extrapolation. 
In Chakravarty et al., the twenty four hour rest period was enforced by admission 
to hospital. Although this is the best way to assure compliance, we felt this was not 
possible both in our study protocol and more importantly, in today's Canadian health care 
system. Most clinicians who are advocates of rest post injection, simply tell their patients 
to rest ifthe injection is performed in the outpatient clirJ.c. The clinicians understand this 
is not ideal however they also realize that the recourses do not exist to admit each and 
every injection patient to hospital for twenty four hours. For this reason, the intervention 
39 
in this trial was to ask patients to rest post injection. It was felt this was more 
representative of an intervention thAt had more real world practicalit-y. Every patient in 
our study group, when asked at their two week follow-up, stated that they had complied 
with the twenty four hour rest period. 
Telephone follow-up for the 2. 6 and 12 week collection points should not affect 
our results. The WOMAC has been validated for use over the telephone with excellent 
agreement between scores obtained in the office (face to face) and those obtained over 
the phone (Bellamy and Campbell et al.). With the local geography and climate, it was 
felt in-person interviews may result in a high number of patients lost to follow-up or less 
than accurate timing for each visit To minimize confusion and inaccuracies, the first time 
(at injection) the WOMAC was completed in person with the study nurse. The patient 
was then given a blank WOMAC sheet to follow along with when the information was 
collected over the phone at the subsequent data collection points. A telephone script was 
used to maintain consistency. 
Neither the patient nor the data collector was blinded in this study. With our 
intervention, blinding the patient was obviously impossible. However, both the rest and 
no rest group had an intervention (the injection). Thus, the satisfaction sometimes 
obtained from simply doing an intervention is negated. 
Our primary outcome measure, the WOMAC, is designed to be straightforward 
which allows it to be self-administered .. The WOMAC questionnaire does not require 
subjective interpretation, the score is simply calculated from the answers given. For this 
reason, it was felt that unblinding the data collector, although not ideal, would not 
represent a major bias. 
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Some selection bias may be present in this study. AU patients recruited were 
referred by a primary care physician for an olihopedic specialist assessment, thus 
possibly selecting out more severe cases of OA for the triaL However, mild cases of OA 
may respond to less invasive modalities (i.e. NSAID's) and not even require intra-
micular steroids. 
A common sub-group of OA is the inflammatory type. These patients present 
with a joint that more closely resembles a primary inflammatory arthropathy with more 
heat, erythema, and effusion. These patients may have a greater response to both the 
injection and the post-injection rest however we did not make this as an inclusion criteria 
or analyze these patients as a subgroup. As the disease is a continuum and without the 
presence of an objective method of selecting out these patients, it was decided to include 
all patients with OA. 
The actual difference in the magnitude of the activity level between the study and 
control groups is unknown. CompliaJlce in the study group seemed acceptable as all 
admitted they had complied with our instructions to rest. No attempt was made to 
determine how much activity the control group actually performed as this would have 
been very difficult to quantify. 
The timing ofthe data collection points was not chosen randomly. Recent 
literature has shown little benefit after one month post-injection (Towheed et at). The 
two-week interval would demonstrate any early benefit. The six-week point would 
measure the deterioration in symptoms that should occur. We felt this is when we may 
see an advantage in the rest group. The twelve-week measurement would demonstrate 
any longer term benefit, if it existed, of the rest We felt at twelve weeks, most patients 
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would have rehl.m"ned to their pre-iiUection clinical symptomatology. This did not occur, 
however, with lowers WOMAC score still evident at the twelve week point when 
compared to pre-injection. 
The most cowmon reason for missing dam was due to re-injection. Patients 
returned to dime before the trial was over, with either increased pain or return of 
discomfort and were re-injected. This was not planned for in trial design. It was felt 
unethical to deny this treatment due to involvement in the trial thus patients were re-
injected at the discretion of their surgeon and further data collection was stopped. 
This group, however, could be insightful regarding the efficacy of the intervention. 
Where they aU from the same group or was their WOMAC score higher at baseline? Of 
the seven patients re-injected, three were from the No Rest group and four from the Rest 
group. This small group of seven were then compared to the rest of the entire sample 
using an independent samples t-test and no significant difference was found in WOMAC 
scores at baseline, week 2, or week 6. The mean WOMAC mean at baseline was higher 
in the reinjected group (Table 7) but due to the small numbers in this group, no definite 
conclusions can be drawn. 
A simple randomization teclli1ique was employed in this study. The patients were 
recruited from several clinics in two hospitals and the use of pre randomized envelopes 
was felt to be impractical. This technique did leave the possibility of having unequal 
numbers in our study and control groups which would have made statistical analysis 
more difficult Fortunately, this problem did not occur, with exactly equal nmnbers 
assigned to each group. It appears, based on the obtained p values of the variables we 
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collected, that om group represented a random sample of the population the groups 
being similar in the variables that were coHectedo 
One of om WOMAC measurements (at Injection) is not affected by the 
intervention and both groups have similar scores at this point, due to our randomizationo 
If simply included in a Repeated Measures A.1\!0V A, it may diminish the magrJrude of 
statistical difference between the rest and the no rest groups and may lead to a very 
conservative p-value 0 To account for this, the baseline data is analyzed as a covariate 
resulting in the test being better referred to as an Analysis of Co-Variance (ANCOVA) 
(Norman et aL) Using convention of P<Oo05 being the level of statistical significance, this 
trial failed to demonstrate any short term clinical benefit from a period of rest after an 
intra-articular corticosteroid injection in the knee for treatment of osteoarthritiso 
Despite the reduction in WOMAC scores from baseline at all data collection 
points for both of the groups, this study does not provide evidence that corticosteroid 
injections provide relief of pain. This was not the objective of the study thus we did not 
include a placebo group to which to compareo We felt that withholding standard care in 
patients refractory to conventional therapy would be unethical. Also, there exist solid data 
that in the short term the steroid injections in the knee are helpful. These patients were 
recruited from a clinic which they were attending for the purpose of treatment for their 
OA. We did not deny anyone this safe, effective form of treatment. 
It is conceivable that there is a trend for t_lf]_e group with no rest to have lower 
WOMAC scores (better outcomes), as nun1.erically the scores were better at all three post 
injection time periods. It is possible that this gap may have continued to widen and at 
some point in time may have represented a statistically significant difference, if larger 
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number of subjects were tested and also if a longer period of follow-up was observed. 
Unfortunately, this trend was not known until aU data was collected and analysed, 
making data collection at other collection points in time impossible. 
This trend was noted approximately one year after the first patient had been 
entered in the trial. Although measurements at 4 and 6 months would have been ideal, it 
was decided to collect the WOMAC scores at one year post-injection. Only twenty-four 
patients at the one-year point had not had further intervention (i.e. another injection, 
arthroscopy, or total knee arthroplasty). Ten were from the rest group and fourteen from 
the no rest group and their WOMAC mean scores were 1.4 (S.D. 1.1) and 1.7 (S.D. 1.0) 
respectively. With the large dropout rate, no useful clinical conclusions could be drawn. 
It is common for patients to state a decreasing clinical benefit with subsequent 
injections. The number of previous injections was recorded in hopes of demonstrating 
this, however the multiple regression analysis failed to prove it. Age and NSAID use also 
could no be shown to have an influence on outcome. 
In recent work, there is both scientific and clinical evidence that rest can be 
detrimental in the quest to relieve pain. In a rat model Okamoto et al., demonstrated that 
sensory afferent fibres were sensitized in a similar fashion by both immobilization and 
inflammation. Highest afferent nerve activity was found inflamed knees during the 
initiation of continuous passive motion after a period of rest. This may explain "'starting 
pain" that patients Vvrith OA experience. The first few movements of an affected joint 
after a period of rest are the most painful, and with continued motion, the discomfort 
unproves. 
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One of the most noteworthy clinical examples of the poor effect of rest on pain 
relief was work on bed rest and its usefulness as a treatr.rnent for acute back paino 
(Malmivaara et al. ). In a randomized trial, the investigators compared forty eight hours of 
bed rest, back-mobilizing exercises, and ordimL.")' activity for treatment of patients with 
acute onset of non-specific low back pain. A more rapid recovery was found in patients 
who were permitted ordinary activity as tolerated that patients in either of the other two 
groups. Although the etiology of acute low back pain is much less understood than OA, 
there is some degenerative component present and this study demonstrates that rest is 
actually deleterious at relieving short-term pain. 
One explanation for our findings may lie in the differing magnitude of the 
inflammatory component in OA and inflammatory arthropathies. With activity having 
been shown to worsen the inflammatory process in a joint (Smith et al.) and this 
inflammatory process being must more severe in RA than OA, one could see how rest for 
a primarily mechanical process such as OA would be less helpful than in patients with 
RA. This may partially explain the differing results obtained by this trial and Chakravarty 
et aL In this trial, the trend at all data collection points, was the total WOMAC index was 
higher (worse outcome) in the patients asked to rest. 
Based on the previous work on rheumatoid patients, we hypothesized that resting 
after a steroid injection would be a simple intervention that may increase the duration and 
magnitude ofreliefo We were unable to prove that in this study. It is presently standard of 
care in our orthopedic department to discharge OA patients from clinic after a cortisone 
injection into the knee with no specific instructions for activity leveL The result from this 
trial does not provide any evidence that will change this current practice. 
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APPENDIX 1 CONSENT FORM 
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F ACUJL TY OF MEDlClfl\,'E -MEMORIAL ll'NNERSITY 1\llEWFOUNDLAJ\fD 
AND 
HEALTH CARE CORPORATION OF ST. JOHN'S 
Consent To Participate l1n Bio-medical Research 
TITLE: Does resting after a cortisone injection improve the pain relief? 
INVESTIGATOR: Dr. Craig Stone, Dr. Proton Rahman 
SPONSOR: Department of Surgery 
You have been asked to participate in a research study. Participation in this study is 
entirely voluntary. You may decide not to participate or may withdraw from the study at 
any time without affecting your normal treatment. 
fuformation obtained from you or about you during this study, which could identifY you, 
will be kept confidential by the investigator. The investigator will be available during the 
study at all times should you have any problems or questions about the study. 
Purpose of the Study: 
Some doctors believe that resting for a short time (24 hours) after a cortisone injection 
improves the pain relief from your arthritis. Others believe it makes no difference and is 
not worth the inconvenience. This research project is designed to help answer t.~s 
question. 
Study Procedure: 
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You and your doctor lr'..ave decided that a cortisone injection into your knee is the next 
step in your treatment If you agree to enter our study, after your injection you will either 
be asked to "rest" for 24 hours OR to go about your usual routine. Rest will involve 
walking only to get home and to do necessary things at home like eating and going to the 
bathroom. You wm be asked to fill out a questionnaire about the pain and function of 
your knee. You will be assigned to either the rest or no rest group by chance. You will 
have a 50 per cent chance of being asked to rest. 
Duration of Participation: 
The questionnaire will be repeated three times over the next several weeks. The later 
questionnaires can be completed over the phone. Your regular follow-up appointments 
with your doctor will not be affected. 
Possible risks. discomforts, or inconveniences: 
If you would be unable to rest for twenty-four hours due to important work or personal 
commitments, do not enter the study. 
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Treatment for those not entering the studv: 
If you do not choose to enter the study for any reason, your knee will be injected and 
your doctor will follow his/her usual suggestions about rest. 
Liabilitv Statement: 
Yom signature indicates your consent and that you have understood the information 
regarding the research study. In no way does this waive your legal rights nor release the 
investigators or involved agencies from their legal and professional responsibilities 
Signature: __________________________________ ___ 
Date: ________________________ _ 
Witness:---------------------
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Study tide: Does resting after a cortisone injection improve the pain relief? 
Name of principal investigator: Dr. N. Craig Stone 
Please check as appropriate 
I have bad the opportunity to ask questions/to discuss this study. 
I have received enough information about the study. 
I understand that I am free to withdraw from the study 
ilfitanytime 
without bavirmg t© give a reasou 
without affecting my future care 
yes 
no 
yes 
yes 
yes l!l!O 
I understand that it is my choice to be in the study and that I may not benefit. yes no 
58 
yes 
Signature: ------------------
Date: ____________ _ 
Witness: 
---------------------------
I have explained this study to the best of my ability. I invited questions and gave answers. I 
believe that the pamdpat fully w.mdentads what is involved in being in the study, any 
potential risks ofthe study and that he o:r she has freely chosen to be in the study. 
Signanrre: ------------------------------
Dme: ________________ _ 
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APPENDIX 2 QUESTIONNAIRE I DATA COLLECTION SHEET 
60 
Today's Date: 
Patient's Name: 
MCP#: 
DOB: 
Telephone #: 
Occupation: 
Knee (RIL): 
DATA FORM 
Rest Post-Knee Injection Study 
INITIAL VISIT 
Clinic Assessment 
Random allocation: D Rest D No Rest 
Have you had any previous cortisone injection into THIS KNEE? 
DNone Dl 02 D3ormore DUnsure 
Have you taken any medication for THIS KNEE in the last 48 hours? D Yes D No 
D NSAIDS D Acetaminophen D Chondroitin Sulphate D Other ___ _ 
Complete WOMAC table for INJECTION VISIT (page 3) 
Date Scheduled: 
WEEK2 
Via Telephone 
-------
Date Completed: ______ _ 
Have you taken any medication for THIS KNEE in the last 48 hours? D Yes D No 
D NSAIDS D Acetaminophen D Chondroitin Sulphate D Other ___ _ 
If you had your time back, would you have had the knee injection? 
0 Yes DNo 
(IF IN REST GROUP) 
Did you rest after your injection? DYes DNo 
Complete WOMAC table for WEEK 2 VISIT (page 3) 
61 
Date Scheduled: 
--------
WEEK6 
Via Telephone 
Date Completed: ______ _ 
Have you taken any medication for H·llS KNEE in the last 48 hours? D Yes D No 
0 NSAIDS D Acetaminophen 0 Chondroitin Sulphate D Other ___ _ 
If you had your time back, would you have had the knee injection? 
DYes DNo 
Complete WOMAC table fo:r WEEK 6 VISIT (page 3) 
Date Scheduled: 
WEEK12 
Via Telephone 
-------
Date Completed: ______ _ 
Have you taken any medication for THIS KNEE in the last 48 hours? D Yes 0 No 
D NSAIDS D Acetaminophen 0 Chondroitin Sulphate D Other ___ _ 
If you had your time back, would you have had the knee injection? 
0 Yes DNo 
Complete WOMAC table fo:r WEEK 12 VISIT (page 3) 
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WOMAC Ouesdonnairt 
Please answer each of these questions on a scale of 0 to 4 where 0 is none and 4 is 
extreme. 
0 h l 48 h vert e ast ours, h h . d owmuc .pam oyou ha ? ve. 
I PAIN Injection I Week 2 I Week6 Week 12 I 
1. Walking on a flat surface ! I ! 
2. Going up or down stairs ! I 
' ! 
3. At night while in bed ! I ' 
4. Sitting or lying 1 I 
5. Standing Upright I I 
Please answer each of these questions on a scale of 0 to 4 where 0 is none and 4 is 
extreme. 
In the last 48 hours ... 
STIFFNESS Injection Week2 I Week6 Week 12 
6. How severe is your stiffness, not I 
pain, after first awakening in the I 
morning? I 
7. How severe is your stiffuess, not 
I pain, after sitting, lying, or resting later in the day? 
Please answer each of these questions on a scale of 0 to 4 where 0 is none and 4 is 
extreme. 
Over the last 48 hours, what degree of difficulty do you have? 
FUNCTION Injection Week2 Week6 Week 12 
8. Descending Stairs 
9. Ascending Stairs I 
1 0. Rising from sitting I ! 
11. Standing 
12. Bending to Floor 
1 13. Walking on Flat I 
14. Getting in and out of the car I 
15. Going Shopping 
l 16. Putting on your Socks 
I 17. Rising from bed 
18. Taking offyour socks 
l 19. Lying in bed 
I 20. Getting in and out of the bath I 
1 21. Sitting I 
' 22. Getting on and off the toilet 
! t" ~ I I i 1 23. Heavy domestiC dut~es 
124. Light Domestic Duties 
I 
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APPENDIX 3 TELEJ!HONE FOLLOW UP SCRPIT 
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T dephone Script 
Hello [participant]. This is [research nurse]. We are calling to foHow up on om 
s~udy of rest after your knee injection. You may remember the questionnaire that you 
completed in the clinic after your first knee injection. This is the same questionnaire that 
you completed in the clinic and we would like to complete it again now over the phone to 
see if there has been any improvement or worsening of your knee. It win take 
approximately 10 minutes. Would you care to complete this for us now? 
Please answer each of these questions on a scale of 0 to 4 where 0 is none and 4 is 
extreme. 
Over the last 48 hours, how much pain do you have? 
Walking on a flat surface 
Going up or down stairs 
At night while in bed 
Sitting or lying 
Standing Upright 
In the last 48 hours ... 
How severe is your stiffness, not pain, after first awakening in the morning? 
How severe is your stiffuess, not pain, after sitting, lying, 
or resting later in the day? __ 
Over the last 48 hours, what degree of difficulty do you have? 
Descending Stairs 
Ascending Stairs 
Rising from sitting 
Standing 
Bending to Floor 
Walking on Flat 
Standing 
Getting in/out car 
Going Shopping 
Putting on Socks 
Rising from bed 
Taking off socks 
Lying in bed 
Getting in/out bath 
Sitting 
Getting on/off toilet 
Heavy domestic duties 
Light Domestic Duties 
********Transfer results to data collection sheet******** 
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AfPENDIX 4 HJlMAN INVESTIGATIONS COMMITTEE APPLICATION 
66 
Human Investigation CmTh1JDlittee- Application Fonn 
Faculty of Medicine- Memorial University ofNewfoundland 
Health Care Corporation ofSt John's 
Forward 20 copies of application and consent fonns to: 
Office of Research (HIC), Room 1759, Health Science Centre. (Phone 737-6974) 
1. Investigators. 
2. Title of study. Include protocol number, if any. 
dates. 
If a indicate program and name of 
Dr.P.Rahman 
3. Starting and ending 
Intra-articular steroid injection for Osteoarthritis of the knee: Effect of post 
injection rest on pain relief and function 
Proposed start date: 
from elate 
2001 
least 4 weeks 
September 
Anticipated cmmol'eW)n date: 
June 2002 
fill. h . fl 'f 4. Pease 1 m t e appropnate m ormatmn, 1 any. Ch k r bl b ec app11ca e oxes. 
Involves 
Hospital or Community Setting Involved 
i Patients or Residents Records Facilities 
Health Science Centre X X 
St. Clare's Mercy Hospital X X 
J 
5. List the main objectives of the investigation. Use mdy the space provided. 
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1. To determine if a short period of rest after an intra-artic1l!llar steroid h'1jecf.ion ilriilproves the lieveli a>"ld 
duration of pain relief in patients wit,~ primary osteoartihritis of the knee. 
What is the scientific 
Osteoarthritis of the knee is a very common clinical entity. It is estimated that 25-30% of people aged 45 to 64 and 
more than 85% of people older than 65 years of age have OA of the knee identifiable on radiographs. mtra-articular 
steroid injections have been used for over fifty years in the treatment of this disease. This treatment modality has 
been shown to provide relief of pain and improve function in these patients for a short period oftime (1 month). It 
does not provide a cure or long lasting benefit. 
Intra-articular steroids have been shown to be safe and have few systemic side effects. They are routinely used as a 
non-operative form of treatment in patients with osteoarthritis of the knee when less invasive modalities such as 
physiotherapy, non-steroidal anti-inflanJtmatory drugs, and activity modifications have failed to provide satisfactory 
pain relief. 
What is the rationale for the 
Physicians providing this form of treatment vary on their post injection recommendations. Some allow the patient to 
, continue with their normal daily activities and others suggest to the patient to rest for a short period (24 hours). 
Proponents of post injection rest feel it results in a more significant and longer lasting pain relief. The proposed study 
wiH help to answer this dinical question. 
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I M~;'~:~;~:eh:~~ ~~=~";~~~~~~:~ ~~cmnenti~~d~: excelilen~~'~i~~~~~file of this treatment. Allergic reactions have , 
been rare and systemic absorption is minimal and causes few, if any, significant problems. One survey of 2231 
orthopaedic surgeons revealed that each used intra-articular steroids on average 150 times per year. 
A recent meta-analysis of studies pert.ah"1ing to the benefits of intra-articular steroids has demonstrated that short-term 
pain relief, up to one month, is provided with t.his treatment when compared with placebo. 
I Only one study exists in the literature that addresses the issue of post injection rest. A study of patients wit.h 
1 rheumatoid arthritis demonstrated that a short period of rest post-injection improved both the duration and level of 
pain relief in the knee. No previous study has addressed this question in osteoarthritic patients. 
and amount 
NONE 
I 
wm any samples be kept after the completion of the YIN if yes, include section 9 on consent form. 
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be 12drcr.lnistered to e,g, 
dose and tho§e t!liat are rmt 
40mg ofMethylprednisolone Acetate will be injected into the painful knee of the patient ooder 
sterile conditions in the clinic setting. 
or chani audit forms to be used: .. ~ttach of each. 
! The WOMAC (Western Ontario and McMaster Osteoarthritis Index}. The pam, stiffuess and function subscales wm aU 
be used. 
9. For studies involvin atients. 
What treatment do YOV now use for patients who would meet the indus ion criteria for this 
h"-tovv' vvoulid you tnanage these did not go Unto this 
For patients not involved in the study, the steroid injection wm be administered and no period ofrest win 
be suggested. The patients win be free to carry on with their routine daily activities. 
!s this an application for a clinical trial? Yes I No 
If yes. what phase is this trial? I H m IV 
What is the design of the trial open, double crossover etc.)? 
10. In the space provided, give a brief description ofthe design of the study, including participant 
selection, interventions and outcome measurement. (Attach one copy of a protocol if available). Do nuot 
ex and this box 
The study group will consist of patients requested to rest. This will involve not returning to work, 
ambulating only to travel home and necessary ambulation at home (eating and bathroom). Twenty-four 
hours of rest will be requested. The control group will be injected and have no specific restrictions applied. 
It win be suggested that they carry on with their usual daily routine. Patients will be randomly assigned to 
each group after the injection is performed. Inclusion criteria will include 1. Primary osteoarthritis of the 
I
. knee. Diagnosis based on clinical and radiographic findings and AAOS definition of OA. 2. Non-invasive 
modalities of treatment, i.e. activity modification, NSAID's, have failed to satisfactorily control symptoms 
i of pain and swelling. 3. Patient available for follow up. 4.Patient's informed consent expressed via I signature on consent form. 
I Exclusion criteria will include: l.Contraindication to intra-articular corticosteroid iniection. Common I examples include undesirable reaction to previous injection and active infection at the injection site. 2. 
I Inability to comply with a period of rest Reasons may include occupation or personal commitments that I would make this rest period unacceptable. The WOMAC be administered immediately post-injection, 
: and via telephone at 2 weeks, 6 weeks and 3 months post injection. 
I 
1 L Pa;."'tici ants. I Number of participants at this site. _94 __ wm pregnant women be excluded? YES 
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Is t:i'tis part of a multi-center study? NO If Yes, what is the total Ellk"Elber ofpa.rtidpants at aH sites? 
be recruited? 
Patients wiH be recruited from rheumatology and orthopaedic outpatient clinics in the Health Care corporation of St 
1 John's. Patients who meet the inclusion criteria wm be approached to participate in the study. 
12. What is the basis for the choice of sample size? (Consider the tota! number of participants for multi-
center studies). 
l The mean and standard deviation for the pain subscale of the WOMAC has previoooly been determined; mean (X= 
10.3) and standard deviation (sd = 4.4). The investigators have decided a 20% change in the WOMAC score to be 
clinically relevant. With such a benign intervention as a period of rest, a small improvement in outcome would be 
clinically importa.11t and would justify the intervention. With. a= 0.05 (Type I error) and~= 0.20 (Type n error), a 
sample size of 39 patients per group is required. This was calculated using a two-tailed test comparing two 
independent groups. Assuming a dropout rate of 10%, 43 patients per group (86 total participants) will be required to 
answer our research question. 
13 What risks, discomforts or inconveniences are involved? 
(a) risks: The small risks associated with. the injection. Infection and allergic reaction are exceedingly rare. 
(b) discomforts: There is a small amount of discomfort associated with the injection. It is often described as similar to 
a routine blood test. 
(c) inconveniences: The study group will be inconvenienced by the period of rest. 
14. Benefits. 
Are there any immediate benefits for the YES Please speciiy. 
Patients in both groups may benefit with. pain relief and improved function as a result of the intra-articular steroid 
injection. 
What wHI be taken to preserve'"'"'"""' 
Patient confidentiality wiH be strictly protected. AU patient records will be treated as hospital charts 
and will be stored safely under lock and key. Any publication or presentation resulting from the 
study will make no reference to patient identification. 
Dr. N. Craig Stone 
Dr. P. Rahman 
Clinical Research. Nurse - TBA 
15. Confidentiality. 
16. Consent process. 
I Who wiH make the initial contact with the participant? Attending physician (orthopaedic or rheumatology) 
vdH obta~rt the consent of the 
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""''·~""'" fo·r consent. 
1 When a patient is identified as a potential study participant, the protocol will be summarized with them. They wm be 
1 given a consent form to read and time wm be allowed for any questions or clarifications. The potential participant I wished to discuss their consent form with others (i.e. family member, family doctor) the steroid injection wiU be 
i delayed until the decision has been made. If this dellay in treatment is unacceptable to the patient, the patient will have 
I their injection performed and not included in the study. 
I 
for feedback to participants. 
Participants will be assured that they can request a copy of any publication and/or presentation that results from the 
study. 
19. Payments. 
(a) Will participants receive: 
reimbursement for expenses incurred? NO 
payment for participation in the study? NO 
(b) Will there be any payment to a third 
I I party for referral of patients? NO 
*Available in the me office and on me web page. 
20. Bud et 
Ptease endose a copy of the 
Will the 
receive t1nandai or other benefit 
21. Ownership of data. 
Please specify on separate sheet according to 
"Guidelines for the Remuneration of Research 
Subjects."* 
! Please specify on separate sheet according to 
1 "Guidelines for Payment of Finders' Fees."* 
I 
If no, where? 
NO 
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the results of the C) NO 
22. Reminders. 
We would like to remind you that it is your responsibility to ensure that permission :is obtained from clinicians, 
departments, institutions or communities whose patients I residents will be involved in the study. 
We would also like to remind you that you must read "Ethical Conduct for Research Involving Humans" (available 
in the HIC Office and on HIC Web Page.) 
Signature of principal investigator. 
Date 
Revised 2000-09-18 
Signature of supervisor, in case of student 
application. 
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